GlassScriptPhysician profile
Nicole Brand
NPI 1295198422
$1,670.18
in general payments reported to CMS, 2019-2025
19 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $152 · 2021: $79.17 · 2022: $570 · 2023: $176 · 2024: $388 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.60 | 2024-2025 | Relistor, Trulance, Xifaxan |
| Fidia Pharma USA INC. | $287.17 | 2021-2022 | |
| Medtronic, INC. | $258.24 | 2023-2024 | Intellis Adaptivestim, Solitaire X, Minimed 780g |
| Stryker Corporation | $150.37 | 2022 | |
| Merz North America, INC. | $110.83 | 2020 | |
| Scilex Pharmaceuticals INC. | $89.18 | 2024-2025 | |
| Asensus Surgical, INC. | $63.84 | 2022 | |
| Si-Bone, INC. | $59.41 | 2022 | |
| Biotronik Nro, INC. | $48.25 | 2023 | Biotronik |
| Takeda Pharmaceuticals U.S.A., INC. | $44.59 | 2022-2023 | Entyvio |
| Medtronic USA, INC. | $41.64 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $30.04 | 2024-2025 | |
| Amgen INC. | $28.92 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.00 | 2023 | Euflexxa |
| Averitas Pharma INC. | $16.70 | 2025 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $16.55 | 2025 | Movantik |
| Biohaven Pharmaceutical Holding Company LTD. | $16.35 | 2022 | |
| Glaxosmithkline, LLC. | $13.34 | 2022 | |
| Protega Pharmaceutials INC | $13.16 | 2024 | Roxybond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Brand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.